Welcome to our dedicated page for Dss SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DSS, Inc. (NYSE American: DSS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly filings, and other documents submitted to the U.S. Securities and Exchange Commission. These filings offer detailed information on DSS’s diversified operations in packaging, biohealth innovation, financial services, alternative trading, real estate, and other business lines, as well as its corporate governance and capital structure.
Through forms such as Form 8-K, DSS reports material events including strategic transactions, changes in auditors, debt conversion agreements, and stockholder meeting results. Examples include disclosures about a debt conversion agreement with Impact BioMedical Inc., changes in the company’s independent registered public accounting firm, and stockholder votes on director elections, auditor ratification, and executive compensation. These documents help investors understand how DSS manages its portfolio, financing arrangements, and oversight functions.
Core financial and operational details are typically found in Form 10-K annual reports and Form 10-Q quarterly reports, where DSS describes its business segments, risk factors, and financial performance across its diversified sectors. In addition, filings related to corporate actions, such as reverse stock splits or listing compliance matters, provide insight into how the company maintains its NYSE American listing and manages its capital markets presence.
On Stock Titan, DSS filings are supplemented with AI-powered summaries that highlight key points, explain complex sections in plain language, and help users quickly identify items such as auditor changes, debt conversions, and governance decisions. Real-time updates from EDGAR ensure that new DSS filings, including Forms 10-K, 10-Q, 8-K, and any insider transaction reports on Form 4, are available promptly, giving investors and researchers a structured view of the company’s regulatory history and ongoing disclosures.
DSS, Inc. entered into a material securities purchase agreement with Alset International Limited under which Alset International will loan DSS $2,450,000 via a convertible promissory note and receive warrants.
The note bears simple interest at 3% per year and may be converted into common stock at $0.74 per share any time before its five-year maturity. The accompanying warrants allow Alset International to buy up to 16,554,055 DSS common shares at an exercise price of $0.93 per share, expiring five years from issuance.
The transaction is a related-party deal because both companies are under the common control of Chan Heng Fai and share several directors, and it is subject to stockholder approval and board and audit committee oversight.
DSS, Inc. reported 2025 revenue of $20.8 million, up 9% from $19.1 million in 2024, driven mainly by a 12% increase in printed products and higher securities commissions. Rental and commercial lending revenues declined as certain real estate assets faced vacancy and loans went on non-accrual.
The company operates four segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management, with a global footprint centered in North America and Asia. In 2024, subsidiary Impact BioMedical completed an IPO, and in 2025 DSS sold its Plano, Texas facility for $9.5 million and its Celios air purification asset for about $1.15 million, using part of proceeds to reduce debt.
As of December 31, 2025, one customer accounted for 29% of consolidated revenue, and five customers represented the majority of trade receivables, highlighting concentration risk. DSS also carried significant secured debt, including a $40.3 million LifeCare loan with about $37 million outstanding that is disclosed as being in default and due, alongside other bank and private loans.
The company held about $17.0 million of net intangible assets tied largely to Impact BioMedical and reports nine issued and over forty pending patents. Management emphasizes a multi-stage growth strategy, targeted 15–20% cost reductions, cybersecurity investments, and potential future IPOs of business units, while also outlining extensive risk factors around indebtedness, listing compliance, intellectual property, and litigation.
DSS, Inc. stockholders holding a majority of voting power have approved, by written consent, an amendment to the 2020 Equity Incentive Plan authorizing up to 3,637,007 shares of common stock for future awards. This pool represents approximately 40% of the 9,092,518 shares outstanding as of January 12, 2026.
The plan supports grants of stock options, restricted stock, stock appreciation rights and other equity or cash awards to employees, directors and consultants, with a 10-year plan term and options priced at no less than fair market value. The information statement also details current ownership, board composition, committee structure, executive and director compensation, and several related-party financings and investments involving entities affiliated with Executive Chairman Ambrose Chan.
DSS, Inc. has obtained written consent from holders of a majority of its voting stock to approve corporate actions without a stockholder meeting, including a major expansion of its 2020 Equity Incentive Plan. The company’s voting securities on the January 12, 2026 record date consisted of 9,092,518 shares of common stock and no preferred shares.
The 2020 Equity Incentive Plan will authorize up to 3,637,007 shares of common stock for issuance, providing capacity for stock options, stock appreciation rights, restricted stock and other equity or cash awards to employees, directors and consultants. As of December 31, 2024, 814,184 shares were available under the plan prior to this increase.
Executive Chairman Ambrose Chan Heng Fai beneficially owns 6,148,664 common shares, or 67.6% of outstanding stock, including positions held through Alset Inc., Alset International Limited, Heng Fai Holdings Limited and Global Biomedical Pte. Ltd., and, with other insiders, controls 67.6% of the company. Independent directors meet NYSE American independence standards and serve on audit, compensation and nominating committees that oversee governance, pay and board composition.
DSS, Inc. completed a firm-commitment underwritten public offering of 900,000 shares of common stock at $1.00 per share. After underwriting discounts, commissions and expenses, the company expects to receive net proceeds of approximately $0.7 million.
DSS granted the underwriter, Aegis Capital Corp., a 45-day option to buy up to an additional 135,000 shares to cover over-allotments. The offering, conducted under an effective Form S-3 shelf registration, closed on February 5, 2026. DSS plans to use the proceeds for general corporate purposes and working capital, and its executives and directors agreed to a 45-day lock-up on share sales.
DSS, Inc. is conducting a primary offering of 900,000 shares of common stock at $1.00 per share, with an underwriter over‑allotment option for up to 135,000 additional shares. Gross proceeds are $900,000, with estimated net proceeds of about $677,000 after underwriting fees and expenses.
Shares outstanding are expected to increase from 9,092,518 to 9,992,518, or up to 10,127,518 if the over‑allotment is fully exercised. The company plans to use roughly $100,000 of the net proceeds for capital expenditures and about $577,000 for general corporate and working capital needs, which may include officer compensation.
The prospectus highlights significant secured indebtedness, including loans that are in default and past due, concentration of revenue in two major customers, prior material weaknesses in internal controls, potential impairment of sizable intangible assets, and the risk of NYSE American delisting, all of which could pressure future results and liquidity.
DSS, Inc. is informing stockholders that a majority written consent has approved corporate actions without holding a meeting, led by holders controlling 67.6% of the voting power as of January 12, 2026. The key action is approval of the Company’s 2020 Equity Incentive Plan with authorization of up to 8,000,000 shares of common stock for future awards, compared with 9,092,518 common shares outstanding on the record date. The plan allows stock options, stock appreciation rights, restricted stock and other equity or cash awards for employees, directors and consultants, and runs until 2035 subject to share limits. The filing also details board composition, committee structures, executive and director compensation, and multiple related-party transactions, including share sales to Alset Inc. and the Executive Chairman and a 1,000,000-share equity bonus to an affiliate in early 2025.
DSS, Inc. reported the results of its 2025 annual meeting of stockholders held on December 3, 2025. A total of 9,092,518 shares of common stock, representing 83.80% of shares outstanding and eligible to vote as of October 6, 2025, were present in person or by proxy, establishing a quorum.
Stockholders elected all seven director nominees — Ambrose Chan Heng Fai, José Escudero, Wai Leung William Wu, Tung Moe Chan, Hiu Pan Joanne Wong, Shui Yeung Frankie Wong, and Lim Sheng Hon Danny — to serve until the next annual meeting. They also ratified the appointment of HTL International, LLC as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 7,401,486 votes for, 178,858 against and 39,793 abstentions.
In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 6,214,296 votes for, 31,186 against and 8,073 abstentions, plus 1,366,582 broker non-votes.
DSS, Inc. reported Q3 2025 results showing higher revenue and a narrower loss. Quarterly revenue was $6.39 million, up from $5.60 million a year ago, driven mainly by printed products and rental income. Operating loss improved to $3.23 million from $4.67 million, and net loss attributable to common stockholders narrowed to $2.30 million from $5.28 million. For the first nine months, revenue reached $16.63 million with a net loss of $9.18 million, improving from $13.68 million and $14.03 million, respectively, in the prior year period.
Liquidity and balance sheet metrics remain tight. Cash and cash equivalents were $7.02 million at September 30, 2025. Current liabilities totaled $54.19 million, including $43.15 million of current long‑term debt, while total stockholders’ equity was $26.11 million. The company completed a $9.5 million real estate sale (recognizing a $0.73 million loss), generated $12.08 million net cash from investing, and used $8.82 million in financing, largely to repay debt. Management disclosed that recurring losses and cash burn raise substantial doubt about continuing as a going concern.
DSS, Inc. filed Amendment No. 1 to its Schedule 14A to include the proxy card that was inadvertently omitted; no other changes were made.
The Annual Meeting is set for December 3, 2025, 9:00 a.m. ET at 275 Wiregrass Pkwy, West Henrietta, NY. Stockholders will vote to elect 7 directors, ratify HTL International, LLC as independent auditor for fiscal 2025, and approve an advisory “say‑on‑pay” resolution for executive compensation.
The Board fixed October 6, 2025 as the record date. Shares outstanding were 9,092,518 as of October 6, 2025. Director elections require more “FOR” than “WITHHOLD” votes; auditor ratification and say‑on‑pay pass with a majority of votes cast. The auditor’s anticipated 2025 fees are disclosed as $205,000–$225,000 for reviews and the annual audit. As of the record date, Heng Fai Ambrose Chan beneficially owned 6,017,985 shares (66.2%), with other notable holders including Alset, Inc. and Alset International Limited.